Advanced search
Publication Cover
Clinical, Cosmetic and Investigational Dermatology Volume 16, 2023 - Issue
Submit an article Journal homepage
148
Views
0
CrossRef citations to date
0
Altmetric
CASE REPORT

Response of Psoriasis with Systemic Lupus Erythematosus to Secukinumab: A Case Report and Review of the Literature

Bowen Dai1 Graduate School, Beijing University of Chinese Medicine, Beijing, 100029, People’s Republic of China;2 Department of Dermatology and Venerology, China-Japan Friendship Hospital, Beijing, 100029, People’s Republic of ChinaView further author information
,
Yanping Bai2 Department of Dermatology and Venerology, China-Japan Friendship Hospital, Beijing, 100029, People’s Republic of ChinaView further author information
,
HongDa Yu1 Graduate School, Beijing University of Chinese Medicine, Beijing, 100029, People’s Republic of China;2 Department of Dermatology and Venerology, China-Japan Friendship Hospital, Beijing, 100029, People’s Republic of ChinaView further author information
,
Qiuchen Huang1 Graduate School, Beijing University of Chinese Medicine, Beijing, 100029, People’s Republic of China;2 Department of Dermatology and Venerology, China-Japan Friendship Hospital, Beijing, 100029, People’s Republic of ChinaView further author information
&
Lei Wang2 Department of Dermatology and Venerology, China-Japan Friendship Hospital, Beijing, 100029, People’s Republic of ChinaCorrespondence[email protected]
View further author information
Pages 3589-3594 | Received 19 Sep 2023, Accepted 07 Dec 2023, Published online: 15 Dec 2023

References

  • Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301–1315. doi:10.1016/S0140-6736(20)32549-6
  • Lau CS, Yin G, Mok MY. Ethnic and geographical differences in systemic lupus erythematosus: an overview. Lupus. 2006;15(11):715–719. doi:10.1177/0961203306072311
  • Yang Y, Yan C, Yu L, et al. The star target in SLE: IL-17. Inflamm Res. 2023;72(2):313–328. doi:10.1007/s00011-022-01674-z
  • Ghoreschi K, Balato A, Enerbäck C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021;397(10275):754–766. doi:10.1016/S0140-6736(21)00184-7
  • Zalla MJ, Muller SA. The coexistence of psoriasis with lupus erythematosus and other photosensitive disorders. Acta Derm Venereol Suppl (Stockh). 1996;195:1–15. doi:10.2340/00015555195115
  • Li Y, Liao W, Chang M, et al. Further genetic evidence for three psoriasis-risk genes: ADAM33, CDKAL1, and PTPN22. J Invest Dermatol. 2009;129(3):629–634. doi:10.1038/jid.2008.297
  • Harley JB, Alarcón-Riquelme ME, et al.; International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN). Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet. 2008;40(2):204–210. doi:10.1038/ng.81
  • Nair RP, Duffin KC, Helms C, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet. 2009;41(2):199–204. doi:10.1038/ng.311
  • Zhang XJ, Huang W, Yang S, et al. Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat Genet. 2009;41(2):205–210. doi:10.1038/ng.310
  • Han JW, Zheng HF, Cui Y, et al. Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet. 2009;41(11):1234–1237. doi:10.1038/ng.472
  • Remmers EF, Plenge RM, A.t L, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med. 2007;357(10):977–986. doi:10.1056/NEJMoa073003
  • Zervou MI, Goulielmos GN, Castro-Giner F, Tosca AD, Krueger-Krasagakis S. STAT4 gene polymorphism is associated with psoriasis in the genetically homogeneous population of Crete, Greece. Hum Immunol. 2009;70(9):738–741. doi:10.1016/j.humimm.2009.05.008
  • Li Y, Cheng H, Zuo XB, et al. Association analyses identifying two common susceptibility loci shared by psoriasis and systemic lupus erythematosus in the Chinese Han population. J Med Genet. 2013;50(12):812–818. doi:10.1136/jmedgenet-2013-101787
  • Kupper TS. Immunologic targets in psoriasis. N Engl J Med. 2003;349(21):1987–1990. doi:10.1056/NEJMp038164
  • Boehncke WH, Prinz J, Gottlieb AB. Biologic therapies for psoriasis. A systematic review. J Rheumatol. 2006;33(7):1447–1451.
  • Sbidian E, Chaimani A, Afach S, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2020;1(1):CD011535. doi:10.1002/14651858.CD011535.pub3
  • Smith CH, Yiu ZZN, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis: a rapid update. Br J Dermatol. 2020;183(4):628–637. doi:10.1111/bjd.19039
  • Callen JP. New psoriasis treatments based upon a deeper understanding of the pathogenesis of psoriasis vulgaris and psoriatic arthritis: a personal appraisal of their use in practice. J Am Acad Dermatol. 2003;49(2):351–356. doi:10.1067/s0190-9622(03)01149-6
  • Yuying Q, Li D, Liu W, et al. Molecular consideration relevant to the mechanism of the comorbidity between psoriasis and systemic lupus erythematosus (Review). Exp Ther Med. 2023;26(4):482. doi:10.3892/etm.2023.12181
  • Langley RG, Sofen H, Dei-Cas I, et al. Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the Phase III ERASURE and FIXTURE trials. Br J Dermatol. 2023;188(2):198–207. doi:10.1093/bjd/ljac040
  • Satoh Y, Nakano K, Yoshinari H, et al. A case of refractory lupus nephritis complicated by psoriasis vulgaris that was controlled with secukinumab. Lupus. 2018;27(7):1202–1206. doi:10.1177/0961203318762598
  • Sato K, Aizaki Y, Yoshida Y, Mimura T. Treatment of psoriatic arthritis complicated by systemic lupus erythematosus with the IL-17 blocker secukinumab and an analysis of the serum cytokine profile. Mod Rheumatol Case Rep. 2020;4(2):181–185. doi:10.1080/24725625.2020.1717741
  • Winchester D, Duffin KC, Hansen C. Response to ustekinumab in a patient with both severe psoriasis and hypertrophic cutaneous lupus. Lupus. 2012;21(9):1007–1010. doi:10.1177/0961203312441982

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.